John G Ullman & Associates Inc. Grows Stock Position in Moderna, Inc. $MRNA

John G Ullman & Associates Inc. increased its holdings in Moderna, Inc. (NASDAQ:MRNA) by 7.7% during the 2nd quarter, Holdings Channel.com reports. The institutional investor owned 16,100 shares of the company’s stock after purchasing an additional 1,150 shares during the quarter. John G Ullman & Associates Inc.’s holdings in Moderna were worth $444,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in the company. VIRGINIA RETIREMENT SYSTEMS ET Al purchased a new position in Moderna in the 2nd quarter valued at about $637,000. Chevy Chase Trust Holdings LLC lifted its holdings in Moderna by 1.2% in the 2nd quarter. Chevy Chase Trust Holdings LLC now owns 179,768 shares of the company’s stock valued at $4,960,000 after purchasing an additional 2,161 shares in the last quarter. Harbour Investments Inc. lifted its holdings in Moderna by 94.4% in the 2nd quarter. Harbour Investments Inc. now owns 1,971 shares of the company’s stock valued at $54,000 after purchasing an additional 957 shares in the last quarter. Concord Wealth Partners lifted its holdings in Moderna by 1,982.5% in the 2nd quarter. Concord Wealth Partners now owns 4,998 shares of the company’s stock valued at $138,000 after purchasing an additional 4,758 shares in the last quarter. Finally, Yousif Capital Management LLC lifted its holdings in Moderna by 6.9% in the 2nd quarter. Yousif Capital Management LLC now owns 44,856 shares of the company’s stock valued at $1,238,000 after purchasing an additional 2,888 shares in the last quarter. 75.33% of the stock is currently owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

A number of research firms have issued reports on MRNA. Wells Fargo & Company restated an “equal weight” rating on shares of Moderna in a report on Sunday, July 13th. Morgan Stanley upped their target price on shares of Moderna from $31.00 to $32.00 and gave the company an “equal weight” rating in a report on Friday, October 10th. Leerink Partners reduced their target price on shares of Moderna from $18.00 to $15.00 and set an “underperform” rating on the stock in a report on Friday, August 22nd. Barclays cut their price objective on shares of Moderna from $40.00 to $31.00 and set an “equal weight” rating on the stock in a report on Monday, August 4th. Finally, Cowen initiated coverage on shares of Moderna in a report on Sunday, July 13th. They set a “hold” rating on the stock. One research analyst has rated the stock with a Strong Buy rating, three have assigned a Buy rating, twelve have issued a Hold rating and five have issued a Sell rating to the stock. Based on data from MarketBeat, the company has an average rating of “Hold” and a consensus price target of $39.93.

Moderna Price Performance

Shares of MRNA stock opened at $26.01 on Friday. The firm has a market cap of $10.16 billion, a P/E ratio of -3.45 and a beta of 2.01. Moderna, Inc. has a 1-year low of $23.15 and a 1-year high of $57.69. The firm’s 50-day simple moving average is $25.91 and its 200-day simple moving average is $27.09.

Moderna (NASDAQ:MRNA) last announced its quarterly earnings data on Friday, August 1st. The company reported ($2.13) earnings per share for the quarter, topping the consensus estimate of ($2.99) by $0.86. The business had revenue of $142.00 million for the quarter, compared to analyst estimates of $116.26 million. Moderna had a negative net margin of 94.31% and a negative return on equity of 25.96%. The company’s revenue was down 41.1% on a year-over-year basis. During the same period in the prior year, the firm posted ($3.33) EPS. Moderna has set its FY 2025 guidance at EPS. Analysts expect that Moderna, Inc. will post -9.61 earnings per share for the current fiscal year.

Moderna Company Profile

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.